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A B S T R A C T
Background
Invasive fungal infections, important causes of morbidity and mortality in critically ill patients, may be preventable with the prophylactic
administration of antifungal agents.
Objectives
This study aims to systematically identify and summarize the eDects of antifungal prophylaxis in non-neutropenic critically ill adult patients
on all-cause mortality and the incidence of invasive fungal infections.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 3, 2005), MEDLINE (1966 to 2
September 2005), and EMBASE (1980 to week 36, 2005). We also handsearched reference lists, abstracts of conference proceedings and
scientific meetings (1998 to 2004), and contacted authors of included studies and pharmaceutical manufacturers.
Selection criteria
We included randomized controlled trials in all languages comparing the prophylactic use of any antifungal agent or regimen with placebo,
no antifungal, or another antifungal agent or regimen in non-neutropenic critically ill adult patients.
Data collection and analysis
Two authors independently applied selection criteria, performed quality assessment, and extracted data using an intention-to-treat
approach. We resolved diDerences by discussion. We synthesized data using the random eDects model and expressed results as relative
risk with 95% confidence intervals.
Main results
We included 12 unique trials (eight comparing fluconazole and four ketoconazole with no antifungal or a nonabsorbable agent) involving
1606 randomized patients. For both outcomes of total mortality and invasive fungal infections, almost all trials of fluconazole and
ketoconazole separately showed a non-significant risk reduction with prophylaxis. When combined, fluconazole/ketoconazole reduced
total mortality by about 25% (relative risk 0.76, 95% confidence interval 0.59 to 0.97) and invasive fungal infections by about 50% (relative
risk 0.46, 95% confidence interval 0.31 to 0.68). We identified no significant increase in the incidence of infection or colonization with the
azole-resistant fungal pathogens Candida glabrata or C. krusei, although the confidence intervals of the summary eDect measures were
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wide. Adverse eDects were not more common amongst patients receiving prophylaxis. Results across all trials were homogeneous despite
considerable heterogeneity in clinical and methodological characteristics.
Authors' conclusions
Prophylaxis with fluconazole or ketoconazole in critically ill patients reduces invasive fungal infections by one half and total mortality by
one quarter. Although no significant increase in azole-resistant Candida species associated with prophylaxis was demonstrated, trials were
not powered to exclude such an eDect. In patients at increased risk of invasive fungal infections, antifungal prophylaxis with fluconazole
should be considered.
P L A I N   L A N G U A G E   S U M M A R Y
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Critically ill patients are at risk of invasive fungal infections, such as those aDecting the bloodstream and other organs. Once established,
such infections are diDicult to treat and result in a high mortality. Results from 12 randomized trials demonstrate that the administration
of antifungal drugs to critically ill patients reduces the incidence of invasive fungal infections by about one half and reduces mortality by
about one quarter. Although no increase in adverse eDects or resistance amongst fungi was reported by these studies, such eDects are not
excluded. However, concerns that the widespread use of antifungal drugs may promote resistance amongst fungi justify their selective use
in patients at greatest risk of fungal infections.
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B A C K G R O U N D
The morbidity and mortality caused by invasive fungal infections
amongst hospitalized patients has increased over recent decades
(Beck-Sague 1993; Jarvis 1995). Immunocompromised patients,
such as those with neutropenia (low white blood cells) and organ
transplant recipients, are at particular risk. However, the incidence
of invasive fungal infections in critically ill intensive care unit
(ICU) and surgical patients is increasingly recognized, amongst
whom up to one half of all cases of invasive candidiasis occur
(Ostrosky 2003). Candida species rank as the fourth commonest
cause of bloodstream infection with a reported incidence of 0.5
to 2% of admissions in unselected ICU patients (Borzotta 1999;
McKinnon 2001; Petri 1997; Pittet 1994; Rangel-Frausto 1999).
Patients in ICUs represent a heterogeneous group amongst whom
certain factors, such as recent abdominal surgery, perforation of
the gastrointestinal tract, dialysis, central venous catheterization,
parenteral nutrition, broad-spectrum antibiotic therapy, and
colonization with Candida species, are associated with increased
risk of invasive fungal infections (Blumberg 2001; Borzotta 1999;
Fridkin 1996; McKinnon 2001;Pittet 1994).
The clinical and economic consequences of invasive fungal
infections in critically ill patients are considerable. Crude mortality
rates of 30 to 40% for candidaemia are commonly reported
(Blumberg 2001; Edmond 1999; Fridkin 1996; Petri 1997), but
uncertainty exists regarding the attributable mortality (Blot 2002;
Leleu 2002; Pelz 2000). Candidaemia has been reported to
be associated with prolonged length of ICU stay (Leleu 2002;
Pelz 2000) and excess economic costs as high as US$44,000
per episode (Rentz 1998). Unfortunately invasive candidiasis is
oPen recognized and treated late, given the non-specific clinical
features and the poor sensitivity and specificity of currently
available diagnostic tests. Recent interest has therefore focused
on preventative strategies. Antifungal prophylaxis, defined as the
commencement of antifungal therapy on the basis of risk factors
for infection or colonization with fungi or both, but without clinical,
microbiological, or radiological evidence of a fungal infection,
reduces the incidence of invasive fungal infections in other high-
risk patient groups, such as neutropenic patients (Gøtzsche 2002;
Kanda 2000) and solid organ transplant recipients (Playford 2004).
Antifungal prophylaxis, encompassing the terms 'prophylaxis',
'pre-emptive treatment', and 'empiric treatment', indicates the
initiation of antifungal therapy prior to the definitive diagnosis
of a fungal infection. However, the relative benefits, harms, and
cost-eDectiveness of antifungal prophylaxis in non-neutropenic
critically ill patients remain undefined. Potential ecological eDects
of widespread antifungal use, including the selection and spread of
resistant fungal strains or species, a well-recognized phenomenon
in bacteria consequent upon antibiotic use (McGowan 1983), are
of particular concern. As a result of this uncertainty, there is no
consensus regarding the use of antifungal prophylaxis in critically
ill patients (Calandra 2002; Ostrosky 2003; Rex 2001; Sobel 2001).
However, considerable variability in clinical practice, with respect
to the indications for prophylaxis, the agents used and the duration
of prophylaxis, occurs (Gauzit 2003). Given that the overwhelming
majority of fungal pathogens in non-neutropenic critically ill
patients involves Candida species, the azole drugs, fluconazole and
ketoconazole, have been the agents in most widespread use for the
prophylaxis and treatment of these infections.
O B J E C T I V E S
The objectives of this review were to determine the benefits and
harms of the prophylactic administration of antifungal agents in
non-neutropenic critically ill patients.
We examined the following primary questions:
1. Is prophylaxis with any antifungal agent(s) associated with
reduced proven invasive fungal infections and total mortality
compared with no prophylaxis?
2. Are some agent(s) alone or in combination more eDicacious than
others?
3. For each agent, does the eDicacy depend upon dose, route of
administration, and duration of prophylaxis?
4. Do some patient subgroups (e.g. medical versus surgical) derive
greater benefit from antifungal prophylaxis than others?
We examined the following secondary questions:
1. Is antifungal prophylaxis associated with reduced suspected
invasive fungal infections?
2. Is antifungal prophylaxis associated with reduced superficial
fungal infections?
3. Is antifungal prophylaxis associated with reduced fungal
colonization?
4. Is antifungal prophylaxis associated with increased colonization
or infection with azole-resistant fungal strains or species?
5. Is prophylaxis with antifungal agent(s) associated with clinically
significant toxicity?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomized controlled trials (RCTs) that
evaluated the eDect of any prophylactic antifungal agent (alone
or in combination with other interventions) in non-neutropenic
critically ill patients.
Types of participants
We considered trials involving adult patients (aged 18 years or
over) and paediatric patients (aged less than 18 years), classified
as critically ill (such as those admitted to an ICU or having recently
undergone an abdominal or other major surgical procedure). We
excluded trials involving neutropenic, neonatal or HIV-infected
patients; patients predominantly with malignancies; or solid organ
transplant recipients, as systematic reviews have been or will be
performed for these patient groups (Gøtzsche 2002; Holmes 2003;
McGuire 2004; Playford 2004; Worthington 2004). We included trials
including non-neutropenic critically ill patients along with other
patient groups if the proportion of these is less than 25% or if data
on non-neutropenic patients were separately provided.
Types of interventions
We considered trials if they involved the randomized comparison
of any antifungal regimen with placebo, no antifungal or another
antifungal regimen.
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The study groups were required to diDer only for the antifungal
regimen under investigation; other cointerventions and aspects of
care, including the routine use of other prophylactic antimicrobial
agents, were required to be the same to avoid potentially
confounded comparisons.
Types of outcome measures
Primary outcomes
Primary outcome measures included:
1. Total (all-cause) mortality.
2. Proven invasive fungal infection. The criteria for proven
invasive fungal infection included a clinical illness consistent
with the diagnosis and either histopathological evidence
of invasive fungal infection, or a positive fungal culture
from one or more sterile site specimens (including blood).
Funguria (as indicated by a positive urine fungal culture),
in the absence of a complicated urinary tract infection,
and fungal oesophagitis were classified as superficial fungal
infections. Where insuDicient information was available to
classify infections, we contacted study authors for clarification.
Otherwise we used the classification and definitions used in
individual studies.
Secondary outcomes
Secondary outcome measures included:
1. Proven or suspected invasive fungal infection. This outcome
measure incorporated both proven invasive fungal infection
cases (defined above) and suspected invasive fungal infection
cases (defined as the initiation of systemic antifungal therapy
without the fulfillment of the criteria for a proven invasive fungal
infection) in trials that reported both outcomes.
2. Superficial fungal infection. Superficial fungal infections were
defined as superficial cutaneous, oropharyngeal, oesophageal
or uncomplicated urinary tract fungal infections.
3. Fungal colonization. Fungal colonization was defined as a
positive fungal culture from any body site that either developed
(if not present at baseline) or persisted (if present at baseline)
during prophylaxis.
4. Proven invasive fungal infection caused by an azole-resistant
Candida species (defined as Candida glabrata, C. krusei,
or another species with documented azole resistance) or a
filamentous fungus (such as Aspergillus species). Note: although
newer azole antifungal agents (such as voriconazole and
posiconazole) have activity against these fungal pathogens, we
will use the term azole-resistant Candida spp. in this review to
denote fluconazole/ketoconazole resistance.
5. Fungal colonization at any body site with azole-resistant
Candida species.
6. Adverse events requiring cessation of study drug(s).
We analysed all outcome measures according to intention-to-treat.
The time point of assessment of outcome measures was at the time
of discharge from ICU or at the end of prophylaxis, whichever was
longer.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases:
The Cochrane Central Register of Controlled Trials (CENTRAL) (Issue
3 2005): the search strategy incorporated MeSH terms for antifungal
agents and for fungal infections.
MEDLINE (OVID: 1966 to 2 September 2005): the search strategy
incorporated MeSH terms and textwords for antifungal agents and
for fungal infections, combined with the Cochrane highly sensitive
search strategy for identifying randomized controlled trials in
MEDLINE (Dickersin 1994).
EMBASE (OVID: 1980 to week 36 2005): the search strategy
incorporated MeSH terms and textwords for antifungal agents
and for fungal infections combined with a highly sensitive search
strategy for identifying randomized controlled trials in EMBASE
(Lefebvre 1996).
We have included the full electronic database search strategies as
presented in Appendix 1.
Searching other resources
We searched the proceedings of major relevant conferences
(including, but not limited to: Interscience Congress of
Antimicrobial Agents and Chemotherapy; American Society for
Microbiology; Infectious Diseases Society of America; European
Congress of Clinical Microbiology and Infectious Diseases;
American Society of Anaesthesiologists; European Society of
Intensive Care Medicine; and Society of Critical Care Medicine).
We searched the reference lists of identified trials and major
reviews.
We contacted researchers active in the field and primary authors of
identified relevant trials for additional published and unpublished
trial data.
We contacted manufacturers of the study drugs for additional
published or unpublished trial data.
We did not apply a language restriction. We accepted letters,
abstracts, and unpublished trials to reduce publication bias. If we
suspected duplicate publication, we contacted the study authors
for clarification, and if confirmed, used the publication with the
longest follow-up data for the review.
Data collection and analysis
Four authors undertook the review (EGP, ACW, TCS, JCC).
Selection of studies
One author (EGP) performed the above search strategy to
identify potentially relevant trials. Two authors (EGP and ACW)
then independently performed each subsequent step of the
selection and review process. The titles and abstracts of identified
studies were initially screened for eligibility. Potentially eligible
studies were subjected to full-text review for methodological
quality assessment (see below) and data extraction (see below).
The authors were not blinded to author, source institution,
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or publication source of trials. Discrepancies were resolved by
discussion with two additional authors (EGP with TCS and JCC).
Data extraction
Two authors independently extracted and collected data on a
standardized paper form. Where important data regarding trial
results were not provided in the primary papers, we contacted
the study authors for clarification. We extracted data, wherever
possible for all randomized patients on an intention-to-treat basis.
One author (EGP) then entered the data into Review Manager
(RevMan 4.2) twice.
Evaluation of study methodological quality
We evaluated the validity and design characteristics of each study
for major potential sources of bias (random sequence generation,
allocation concealment, blinding, intention-to-treat analysis, and
completeness of follow-up) (Higgins 2005). We assessed each study
quality factor separately.
Random sequence generation:
Adequate: Method used that would generate random sequence
(e.g. random number generator, toss of coin).
Unclear: No information on random sequence generation
available.
Inadequate: Alternate medical record numbers or other
nonrandom sequence generation.
Allocation concealment:
Adequate: Allocation method described that would not allow
investigator or participant to know or influence intervention
group before eligible participant entered into study (e.g. central
allocation, sealed opaque envelopes).
Unclear: No information on allocation method available.
Inadequate: Allocation method such as alternate medical record
numbers or unsealed envelopes, open allocation sequence, or
any information in the study that indicated that investigators or
participants could influence intervention group.
Blinding:
We evaluated whether patients, study investigators, outcome
assessors, or data analysis personnel were blinded to treatment
allocation.
Intention-to-treat (ITT) analysis:
Yes: Specifically reported by authors that ITT analysis was
undertaken and confirmed on study assessment, or not stated but
evident from study assessment that ITT analysis was undertaken.
Unclear: Reported by authors that ITT analysis was undertaken but
unable to be confirmed on study assessment, or not reported and
unable to be confirmed on study assessment.
No: Lack of ITT analysis confirmed on study assessment (patients
who were randomized were not included in the analysis because
they did not receive study intervention, they withdrew from
the study, or were not included because of protocol violation)
regardless of whether ITT analysis was reported.
Completeness of follow-up:
Percentage of randomized participants with outcome data at
defined study endpoint.
Data analysis
We analysed data using relative risks and 95% confidence intervals
(CI). We assessed heterogeneity across trials with a test of
homogeneity (χ2 on k-1 degrees of freedom), with p < 0.1
considered significant. We also applied a test of inconsistency
(I2 ) measuring the proportion of total variation in the estimates
of treatment eDect due to heterogeneity between trials (Higgins
2003). We pooled the results from diDerent trials using a random
eDects model and compared with a fixed eDect model in a
sensitivity analysis. We performed subgroup analyses according
to clinical characteristics (such as definition of invasive fungal
infection, proportion of surgical patients, and medical versus
surgical patients) and antifungal prophylaxis regimens (diDerent
agents, systemic versus non-absorbable, dose, duration, and route
of administration). We performed sensitivity analyses comparing
the random eDects model with a fixed eDect model. In a further
sensitivity analysis, we assessed the eDect of study methodological
quality.
We assessed for publication bias using a funnel plot (log relative risk
for eDicacy versus 1/standard error) (Egger 1997).
We calculated the number needed to treat (NNT) using the pooled
estimate of relative risk and various assumptions of baseline risk,
whereby NNT = 1÷ [(baseline risk - (baseline risk ⋅ RR)]. We
calculated the 95% confidence intervals of the NNT as described
(Altman 1998).
R E S U L T S
Description of studies
From the initial search strategy (2228 potential studies), we
identified 33 references as potentially relevant and retrieved these
for further assessment (Additional Figure 1). Of these, 15 references
(publications and abstracts) reporting twelve trials were eligible for
inclusion in this review (see 'Characteristics of included studies':
Ables 2000; ARDS Network 2000; Eggimann 1999; Garbino 2002; He
2003; Jacobs 2003; Parizkova 2000; Pelz 2001; Sandven 2002; Savino
1994; Slotman 1987; Yu 1993). These twelve trials involved 1606
randomized patients (range, 38 to 292 patients per trial). Although
pharmaceutical companies provided some information, no unique
trials were identified. All identified trials were published in full: 11
in English and one in Czech (Parizkova 2000).
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Figure 1.   Search results
 
Eight trials compared fluconazole with no antifungal (Ables 2000;
Eggimann 1999; Garbino 2002; He 2003; Jacobs 2003; Parizkova
2000; Pelz 2001; Sandven 2002) and four ketoconazole with
no antifungal or a nonabsorbable agent (Savino 1994; Slotman
1987; ARDS Network 2000; Yu 1993). All trials but two (He 2003;
Sandven 2002) were restricted to ICU patients. Post-surgical
patients comprised more than 75% of trial participants in six trials
(Eggimann 1999; Pelz 2001; Sandven 2002; Savino 1994; Slotman
1987; Yu 1993), 50 to 75% in two (Garbino 2002; Jacobs 2003), 30
to 50% in two (Ables 2000; Parizkova 2000), and not stated in two
(ARDS Network 2000; He 2003). No trials directly compared diDerent
marketed systemic antifungal agents, although one trial compared
fluconazole and control with "garlicin" (He 2003).
Reporting of outcomes was variable (see Additional Table 1).
Invasive fungal infections were reported in ten trials. Six trials
(Eggimann 1999; Garbino 2002; Jacobs 2003; Parizkova 2000; Pelz
2001; Slotman 1987) reported criteria that were consistent with
our definition (i.e. restricted to positive culture or histological
findings,or both, from sterile site/deep tissue specimens), whereas
four trials (Ables 2000; He 2003; Sandven 2002; Savino 1994)
included positive cultures from one or more superficial sites
as evidence of invasive infection, which we would consider
representing either colonization or superficial infection (Additional
Table 1). Other outcomes were even more variably reported,
particularly with respect to the fungal species causing infection,
colonization, or both.
Ables et al (Ables 2000) included patients at least 14 years
of age admitted to a single ICU either with a diagnosis of
trauma ("code trauma", "trauma consult" or "trauma alert") or
who had undergone intra-abdominal or intrathoracic surgery.
Furthermore, patients were required to have an anticipated
length of ICU stay of more than 48 hours and at least one
"risk factor" manifest within 48 hours of ICU admission (central
venous catheter placement, administration of total parenteral
nutrition (TPN), artificial ventilation for more than 24 hours, or
treatment with broad-spectrum antibiotics). Reported baseline
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characteristics included mean age (44 years), mean APACHE II score
(18), trauma (70%), intra-abdominal or intra-thoracic surgery, or
both (30%), and malignancy (3%). Patients were randomized to
receive either fluconazole (800 mg initially followed by 400 mg daily
intravenously, orally, or enterally) or placebo (given by same route
of administration) for the duration of ICU stay.
The ARDS Network trial (ARDS Network 2000) included patients
aged at least 18 years admitted to 24 ICUs who were ventilated
and who developed acute lung injury or ARDS (impaired
oxygenation and bilateral pulmonary infiltrates). Reported baseline
characteristics included mean age (53 years), mean APACHE III score
(81.3), sepsis (31%), and trauma (10%).Patients were randomized to
receive either ketoconazole (400 mg daily enterally) or placebo for
21 days or until more than 48 hours of unassisted ventilation was
achieved.
Eggimann et al. (Eggimann 1999) included patients at least 16 years
of age admitted to two ICUs with recent abdominal surgery and who
had recurrent gastrointestinal perforation or anastomotic leakages
that were either suspected or confirmed by surgery. Reported
baseline characteristics included median age (57 to 63 years),
median APACHE II score (13), gastrointestinal malignancy (37%),
pancreatitis (10%), antibiotics (100%), and fungal colonization
(40%). Patients were randomized to receive either fluconazole (400
mg daily intravenously) or placebo until "complete resolution of the
intra-abdominal disease".
Garbino et al. (Garbino 2002) included patients over 18 years of
age admitted to a single ICU who were mechanically ventilated
for at least 48 hours and expected to remain so for an additional
72 hours. All patients received selective decontamination of the
digestive tract with oral polymyxin B, neomycin, and vancomycin.
Reported baseline characteristics included mean age (54.3 years),
mean APACHE II score (19.4), abdominal surgery (20%), other
surgery (40%), malignancy (15%), antibiotics (39%), TPN (28%),
and fungal colonization (48%). Patients were randomized to
receive fluconazole (100 mg daily intravenously) or placebo until
withdrawal from mechanical ventilation.
He et al. (He 2003) included patients with pancreatitis and at
least one "predisposing factor" for fungal infection ("gerontism",
diabetes, "dysfunction of one or more organs", hyperglycaemia,
central venous catheter, TPN, urinary catheterization, "operation",
gastrointestinal fistula, "ICU", ventilated at least five days, broad-
spectrum antibiotics at least five days, or "super" broad-spectrum
antibiotics at least three days). Reported baseline characteristics
included mean age (50.2 years) and mean APACHE II score (12.2),
Patients were randomized to receive fluconazole (100 mg daily
intravenously), "garlicin" (120 mg daily intravenously), or neither.
Treatment was continued "until relief of predisposing factors".
Jacobs et al. (Jacobs 2003) included patients admitted a single ICU
with a diagnosis of septic shock (according to criteria established
by the American Society of Chest Physicians/Critical Care Society
Consensus Conference) within 24 hours of onset, from either intra-
abdominal sepsis or nosocomial pneumonia. Reported baseline
characteristics included pneumonia (52%), intraabdominal sepsis
(48%), surgery (65%), mean APACHE II score (18.4), and fungal
colonization (6%). Patients were randomized to receive either
fluconazole (200 mg daily intravenously) or placebo for the duration
of the septic shock.
Parizkova et al. (Parizkova 2000) included patients aged at least 18
years of age admitted to a single ICU within five days of admission
who had received at least 24 hours of antibiotic therapy and
at least 48 hours of mechanical ventilation. Reported baseline
characteristics included mean age (44.5 years), mean APACHE
II score (23), gastrointestinal surgery (37%), TPN (97%), broad-
spectrum antibiotics (66%), and central venous access (100%).
Patients were randomized to receive either fluconazole (100 mg
daily intravenously) or no fluconazole until ICU discharge.
Pelz et al. (Pelz 2001) included patients admitted to a single ICU
with an expected length of stay of at least 3 days. Reported baseline
characteristics included median age (63 to 66 years), median
APACHE III score (63 to 65), surgery (91%), TPN (9%), antibiotics
within 48 hours of ICU admission (29%), central venous access
(95%), malignancy (29%), and fungal colonization (79%). Patients
were randomized to receive either fluconazole (800 mg loading
then 400 mg daily enterally) or placebo until ICU discharge.
Sandven et al. (Sandven 2002) included patients from 13 hospitals
with intraabdominal perforation or anastomotic leakage. Reported
baseline characteristics included median age (60 to 68 years),
surgery (100%), antibiotics for at least three days (14%), and
malignancy (40%). Patients were randomized to receive either
fluconazole (400 mg intravenously) or placebo as a single dose.
Savino et al. (Savino 1994) included all patients admitted to a single
ICU for more than 48 hours with an expected ICU length of stay of
at least 48 hours. Reported baseline characteristics included mean
age (54 years), mean APACHE II score (11.3), TPN (42%), surgery
(79%), and malignancy (27%). Patients were randomized to receive
ketoconazole (200 mg daily enterally), clotrimazole (10 mg three
times daily enterally), nystatin (2 million units four times daily
enterally), or no antifungal until ICU discharge.
Slotman and Burchard (Slotman 1987) included patients admitted
to a single surgical ICU with at least three of the following: age
greater than 40 years, second- and third-degree burns covering
greater than 30% of body surface area, antibiotics greater than
seven days, three or more antibiotics, severe sepsis unresponsive to
antibiotics, diabetes, steroids greater than seven days, acute renal
failure, immunosuppressive therapy or chemotherapy, advanced
malignancy, TPN, multitrauma, serum glucose greater than 11.1
mmol/L, intra-abdominal abscess, peritonitis, or severe head
injury. Patients with fungal colonization at baseline were excluded
post-randomization. Reported baseline characteristics included
median age (59 to 65 years), intra-abdominal surgery (39%), other
surgery (59%), TPN (25%), antibiotics greater than seven days
(26%), malignancy (11%), and corticosteroids (5%). Patients were
randomized to receive either ketoconazole (200 mg daily enterally)
or placebo for 21 days or until ICU discharge.
Yu and Tomasa (Yu 1993) included patients aged at least 16
years admitted to a single surgical ICU with a diagnosis of
sepsis. Reported baseline characteristics included mean age (53.2
years), mean APACHE II score (13), and mean number of surgical
procedures (1.6 per patient). Patients were randomized to receive
either ketoconazole (400 mg daily enterally) or placebo for 21 days
or until ICU discharge.
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Risk of bias in included studies
Although imperfect, the overall methodological quality of the
included trials was high (see 'Characteristics of included studies').
Random sequence generation
Adequate random sequence generation was specifically reported
in five trials (Ables 2000; ARDS Network 2000; Eggimann 1999; Pelz
2001; Sandven 2002) and unclear in the other seven.
Allocation concealment
Adequate allocation concealment was specifically reported in
seven trials (ARDS Network 2000; Eggimann 1999; Garbino 2002;
Jacobs 2003; Pelz 2001; Sandven 2002; Savino 1994) and unclear in
the other five.
Blinding
Blinding of study participants and investigators was reported
in nine trials (Ables 2000; ARDS Network 2000; Eggimann 1999;
Garbino 2002; Jacobs 2003; Pelz 2001; Sandven 2002; Slotman
1987; Yu 1993), with three of these also specifically reporting
blinding of outcome assessors (ARDS Network 2000; Eggimann
1999; Pelz 2001).
Intention-to-treat analysis
Intention-to-treat analysis was apparent in seven trials (ARDS
Network 2000; He 2003; Jacobs 2003; Parizkova 2000; Pelz 2001;
Sandven 2002; Yu 1993).
Completeness of follow-up
Post-randomization exclusions were greater than 10% in two trials
(Eggimann 1999; Slotman 1987).
E?ects of interventions
Total mortality
(see Analysis 1.1)
Although total mortality rates were very variable in the control
arms of the seven fluconazole trials reporting this outcome (range
0-54%, mean 26%), there was no significant heterogeneity in the
observed eDect of fluconazole across these trials (χ2 = 8.73, df
= 6, p = 0.19; I2 = 31.3%). One trial (Jacobs 2003) demonstrated
a significant mortality reduction (RR 0.41, 95% CI 0.2 to 0.83)
with fluconazole, with four other trials (Eggimann 1999; Garbino
2002; Pelz 2001; Sandven 2002) showing a small, non-significant
benefit. The summary relative risk favoured fluconazole, but was
not significantly less than 1.0 (RR 0.77, 95% CI 0.56 to 1.07).
Mortality in the control arms of the four ketoconazole trials ranged
from 16-42% (mean 25%), with some heterogeneity evident (χ2
= 6.28, df = 3, p = 0.1, I2 = 52.3%). The results of three trials
(Savino 1994; Slotman 1987; Yu 1993) favoured ketoconazole, with
the pooled analysis demonstrating a non-significant mortality
reduction (RR 0.68, 95% CI 0.42 to 1.12).
Across all eleven trials, the results were homogeneous ( χ2 = 14.81,
df = 10, p = 0.14, I2 = 32.5%), demonstrating a significant reduction
in total mortality by about 25% (RR 0.76, 95% CI 0.59 to 0.97).
Invasive fungal infections
(see Analysis 1.2)
Fluconazole significantly reduced the incidence of proven invasive
fungal infections by about one half (RR 0.47, 95% CI 0.32 to 0.71).
One trial (Parizkova 2000) did not report any proven infections,
whereas amongst the other seven fluconazole trials, the incidence
ranged from 3% to 41% (mean 15%). Despite diDerences in
the dose, route of administration, and duration of fluconazole
prophylaxis, there was no significant heterogeneity in the relative
risk reduction across studies (χ2 = 1.12, df = 6, p = 0.98, I2 = 0%).
Amongst the two ketoconazole trials that reported invasive
infections, no significant reduction was demonstrated, although
confidence intervals were wide (RR 0.3, 95% CI 0.07 to 1.31).
Across all trials of both fluconazole and ketoconazole, the results
were homogeneous (χ2 = 1.82, df = 8, p = 0.99, I2 = 0%), with a
significant reduction in invasive infections by about one half (RR
0.46, 95% CI 0.31 to 0.68).
Proven or suspected invasive fungal infections
(see Analysis 1.5 and Analysis 1.6)
Fluconazole prophylaxis did not significantly reduce the incidence
of suspected invasive fungal infections (empiric antifungal use)
amongst the four trials that reported this outcome, although some
heterogeneity was evident (χ2 = 6.72, df = 3, P = 0.08, I2 = 55.4%) and
the confidence intervals were wide (RR 1.14, 95% CI 0.25 to 5.13).
The incidence of suspected invasive fungal infections in the control
arms of the fluconazole trials ranged from 1% to 5% (mean 3%).
The combined incidence of proven and suspected invasive fungal
infections in the control arms of the four fluconazole trials reporting
this outcome ranged from 14% to 22% (mean 17%). Fluconazole
prophylaxis was associated with a nonsignificant reduction in their
incidence (RR 0.64, 95% CI 0.4 to 1.02).
Superficial fungal infections
(see Analysis 1.7)
The incidence of superficial fungal infections in the control arm of
the three fluconazole trials that reported this outcome ranged from
3% to 12% (mean, 6%). Fluconazole prophylaxis demonstrated
a non-significant reduction in superficial fungal infections (RR
0.59, 95% CI 0.27 to 1.29), with no significant heterogeneity
demonstrated across these three trials (χ2 = 1.12, df = 2, P = 0.57, I2
= 0%).
Fungal colonization
(see Analysis 1.8)
Fluconazole prophylaxis reduced the incidence of fungal
colonization by about one half (RR 0.55, 95% CI 0.42 to 0.74):
this eDect was homogenous across the four trials reporting fungal
colonization (χ2 = 3.61, df = 3, P=0.31, I2 = 16.9%). Ketoconazole
also reduced fungal colonization (RR 0.66, 95% CI 0.47 to 0.94),
with no significant heterogeneity demonstrated across the three
trials (χ2 = 0.83, df = 2, P = 0.66, I2 = 0%). Across the fluconazole
and ketoconazole trials, the eDect on fungal colonization was
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homogenous (χ2 = 4.72, df = 6, P = 0.58, I2 = 0%). Reporting of fungal
colonization did not allow for stratification of colonized patients
into those with or without fungal infection.
Infection and colonization with azole-resistant fungi
(see Analysis 1.3, Analysis 1.4 and Analysis 1.9)
Infections with C. glabrata or C. krusei were documented in four
of the six fluconazole trials that provided data on the species of
invasive fungal pathogens (Ables 2000; Eggimann 1999; Garbino
2002; Pelz 2001). Amongst these four trials, infections with C.
glabrata or C. krusei accounted for 16% of all invasive infections in
the control arms and 21%in the fluconazole arms. The incidence
of proven invasive infections caused by azole-resistant Candida
species was not significantly increased with either fluconazole (RR
0.66, 95% CI 0.22 to 1.96) or ketoconazole prophylaxis (RR 0.34, 95%
CI 0.01 to 8.14).
Fungal colonization with C. glabrata or C. krusei occurred in 6% and
15% in the control and fluconazole arms, respectively. Although no
significant eDect of fluconazole on colonization with azole-resistant
Candida species was demonstrated, three of the four fluconazole
trials did report greater colonization rates and the confidence
intervals around the pooled estimate were very wide (RR 1.74, 0.64
to 4.71).
Adverse events
(see Analysis 1.10)
Adverse events requiring cessation of systemic antifungal
prophylaxis were very uncommon and did not occur more
frequently than in the control arms.
Subgroup and sensitivity analyses
(see Additional Table 2)
In subgroup analyses, no obvious eDect of clinical characteristics
or antifungal prophylaxis regimen was evident. Sensitivity analyses
similarly did not demonstrate an eDect of analysis method (random
eDects or fixed eDect models) or study methodological quality.
Publication bias
(see Additional Figure 2 and Additional Figure 3)
Although trial numbers were relatively small, some degree of
asymmetry in the funnel plot of precision by eDect size was evident,
with a relative absence of trials reporting a lack of benefit from
antifungal prophylaxis.
 
Figure 2.   Funnel plot for systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal; outcome =
total mortality
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Figure 3.   Funnel plot for systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agents;
outcome = proven invasive fungal infection
 
D I S C U S S I O N
This meta-analysis demonstrates that antifungal prophylaxis in
non-neutropenic critically ill patients reduces proven invasive
fungal infections by approximately one half and total mortality by
approximately one quarter.
Although none of the individual fluconazole trials demonstrated
a significant reduction in invasive infections, the pooled result
was highly significant. Furthermore, the eDicacy of fluconazole
was remarkably consistent across the studies despite considerable
diDerences in the dose, duration, route of administration, and
other clinical and methodological aspects. This suggests that the
results are generalizable to a diverse range of clinical situations.
Assuming a baseline incidence of invasive fungal infections
amongst unselected critically ill patients of 2% (Rex 2001), 94
patients would require fluconazole prophylaxis to prevent one
infection. This estimate varies according to risk (see Additional
Table 3): ranging, for example, from nine amongst higher risk
patients (with an approximate 20% incidence) to 188 amongst
lower risk patients (with an approximate 1% incidence). A similar
- albeit non-significant - eDect was observed with ketoconazole on
the basis of two trials reporting this outcome.
Demonstration of a beneficial eDect of antifungal prophylaxis on
total mortality is novel and important. The point estimates of
seven of the 11 trials favoured antifungal prophylaxis, whereas two
showed no benefit. Overall there was no significant heterogeneity
with results across the trials. The pooled analysis for fluconazole
prophylaxis suggests a 23% mortality benefit, with relatively
wide confidence intervals (from a 7% hazard to a 44% benefit).
However, inclusion of the ketoconazole trials in the pooled
analysis demonstrates a significant result of about the same
magnitude (24% mortality benefit, 95% CI 3% to 41%). These
findings are highly encouraging. Although the confidence intervals
are wide and individually only one trial reported a significant
mortality benefit, seven of the other ten trials did demonstrate a
nonsignificant benefit. However, whether this mortality benefit is
mediated through preventing invasive fungal infections remains
uncertain. Reported crude mortality rates associated with such
infections in critically ill ICU patients which range between 40%
and 60% (Blumberg 2001; Edmond 1999; Fridkin 1996; Petri 1997)
do not account for the confounding eDect of severity of illness.
Estimates of the attributable mortality from epidemiological
studies comparing the mortality of infected with uninfected
patients matched for severity of illness, have yielded conflicting
results. We must note the diDiculties of adequately accounting
for the influence of all factors confounding the association
between critical illness, fungal infections, and mortality: two
studies demonstrated no significant attributable mortality (Blot
2002; Pelz 2000) whereas one demonstrated a 31% attributable
mortality (Leleu 2002). Given an uncertain attributable mortality,
it remains possible that merely preventing fungal infections
may not prevent deaths in critically ill patients who are at
risk of death from other underlying conditions. Of note is that
antifungal prophylaxis has not been demonstrated to reduce
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total mortality in other high-risk patients, such as neutropenic
patients (Gøtzsche 2002) or solid organ transplant recipients
(Playford 2004). Fungal-related mortality may be reduced with
antifungal prophylaxis amongst neutropenic patients (Kanda
2000); however we deliberately did not assess this outcome
in this study, as we considered the attribution of deaths to
fungal infections imprecise and subjective, and therefore prone
to bias. Ketoconazole and fluconazole exert anti-inflammatory
and immunomodulatory eDects in addition to their antifungal
activity (Williams 1992; Zervos 1996), and other mechanisms
may therefore contribute to any mortality benefit. Indeed such
eDects provided the rationale for three of the ketoconazole and
one of the fluconazole trials in patients with acute respiratory
distress syndrome or septic shock (ARDS Network 2000; Jacobs
2003; Slotman 1987; Yu 1993). In summary, this systematic review
suggests that azole prophylaxis reduces total mortality in critically
ill ICU patients consistently across the available trials and, when
pooled, this mortality benefit is significant. Although promising and
potentially clinically important, the identification of those patient
subsets, amongst the typically heterogeneous ICU population, that
are likely to derive the greatest benefit remains an important
objective. Confirmation of this mortality benefit in appropriately
powered clinical trials amongst such patients is warranted.
The selection of resistant fungal species is a major potential adverse
consequence of widespread antifungal use. Certain Candida
species, such as C. glabrata and C. krusei, and most filamentous
fungi, including Aspergillus species, are intrinsically or relatively
fluconazole-resistant. The de novo development of fluconazole-
resistance amongst susceptible species and the emergence of
intrinsically resistant species have been associated with the use
of antifungal agents, particularly amongst neutropenic or HIV-
infected patients (Abi-Said 1997; Gleason 1997; Johnson 1995;
Law 1994; Nguyen 1996). Whether such use amongst critically ill
ICU patients has resulted, or will result, in a similar phenomenon
remains uncertain. In the fluconazole trials reporting the species
of infecting fungal pathogens, no significant increase in invasive
infections or colonization caused by C. glabrata or C. krusei
was demonstrated, although more patients were colonized with
these species in the fluconazole arms of three of four trials.
The wide confidence intervals around these pooled estimates
reflect relatively small event rates and insuDicient sample sizes.
Thus, that fluconazole prophylaxis may predispose to infection
or colonization with azole-resistant fungal species cannot be
excluded from the available studies and further studies involving
the characterisation and susceptibility testing of fungal isolates,
an appropriate timeframe, and suDicient statistical power are
required.
The trials included in this review are insuDiciently powered to
exclude adverse toxic events. Ketoconazole - and to a lesser
extent fluconazole - have been associated with hepatotoxicity and
clinically-important drug interactions. The likelihood and severity
of such events with routine antifungal prophylaxis require careful
consideration.
The major limitation of this systematic review is the relatively small
number of trials and their small sample sizes causing imprecision
of pooled estimates. We sought to maximize study retrieval by
employing a comprehensive search strategy encompassing the
major computerized databases without language restriction, major
conference proceedings, unpublished studies, and review articles.
We approached major pharmaceutical companies marketing
antifungal agents, but identified no additional or unpublished
studies. Despite these eDorts, some degree of funnel plot
asymmetry was evident, which suggests the possibility of
publication bias.
The methodological quality of studies in this review, as reported,
was generally of high standard. In more than half of the
trials, adequate allocation concealment, an important potential
source of bias if inadequate (Schultz 1995) was reported. As
invasive fungal infections are oPen diagnosed with some degree
of uncertainty and subjectivity, blinding of outcome assessors
with respect to treatment allocation would be an important
precaution to minimize bias. However, this precaution was
specifically reported in only three trials. Despite progress toward
standardization (Ascioglu 2002), a varied, and oPen conflicting,
range of diagnostic criteria for invasive fungal infections has been
published (Ascioglu 2001). This problem was evident amongst the
trials reviewed here. We therefore, wherever possible, restricted
the diagnosis to patients with compatible clinical features in
whom fungi were demonstrated in blood or deep tissue specimens
by histopathology, culture, or both. Four trials also included
positive cultures from nonsterile site specimens as evidence of
invasive infections making independent classification of infections
impossible. Although in this review, the direction and magnitude
of trial results did not appear to correlate with the presence or
absence of reported study methodological quality parameters, we
urge the incorporation and reporting of methodological quality
parameters and the adoption of standardized diagnostic criteria for
future trials.
Despite heterogeneity of the clinical as well as the methodological
aspects of the trials, the results for the major outcomes were
remarkably homogeneous. This finding suggests that pooled
estimates are both robust and applicable across a wide range of
clinical situations encountered with critically ill patients. Although
likely that diDerent antifungal regimens have diDerent eDicacies,
the results of this meta-analysis suggest that, overall, they are
of a similar magnitude. Nevertheless, given the lack of head-
to-head comparative trials, inferences regarding the superiority
of diDerent doses, routes of administration, and durations of
antifungal prophylaxis are not possible. Fewer data are available for
ketoconazole, although the results of this review indicate an overall
similar eDect to fluconazole. This is an interesting result, given the
poor and erratic bioavailability of the oral formulation. However,
firm conclusions regarding the relative eDicacies of fluconazole
and ketoconazole are restricted by the lack of direct head-to-head
comparative trials.
Other antifungal agents, such as itraconazole, voriconazole,
posiconazole, caspofungin, and amphotericin B, possess broader
spectra of activity than fluconazole, but have not been assessed
in randomized controlled trials of prophylaxis in non-neutropenic
critically ill patients. Given that Candida species cause the
overwhelming majority of infections in such patients and the
demonstrated eDicacy and safety of fluconazole, there may be little
rationale for their use. Such agents may be justified in situations
where fluconazole-resistant candida infections are prevalent,
although their routine use may simply exert additional selection
pressure and an increase in resistant isolates.
Given its demonstrated eDicacy in preventing fungal infections,
should fluconazole prophylaxis be adopted in critically ill patients?
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Amongst such patients, the risk of fungal infections varies
from patient to patient and antifungal prophylaxis should
therefore be instituted selectively to patients at increased
risk, rather than universally. Many risk factors for fungal
infections have been defined (Ostrosky 2003; Paphitou 2005)
and should be incorporated into decisions regarding prophylaxis
(see Additional Table 3). However, the accurate identification of
patients at increased risk requires the further refinement and
validation of predictive risk assessment algorithms (Ostrosky 2003;
Paphitou 2005). Furthermore, the cost-eDectiveness of antifungal
prophylaxis strategies has not been defined - awaiting, in part, a
clearer understanding of the attributable clinical and economic
consequences of invasive fungal infections in critically ill patients.
Finally, as the selection or generation of resistance to antifungal
agents among fungal pathogens remains a major potential
concern, further study quantifying such potential ecological
eDects is required before the widespread adoption of antifungal
prophylaxis can be recommended.
In summary, this systematic review and meta-analysis
demonstrates that antifungal prophylaxis with fluconazole or
ketoconazole reduces invasive fungal infections and total mortality
across a broad range of clinical settings in non-neutropenic
critically ill patients. Antifungal prophylaxis is thus recommended
for critically ill patients at increased risk of invasive fungal
infections. Although no significant diDerence in the eDect of
fluconazole and ketoconazole was demonstrated, fluconazole is
preferred given the greater available evidence-base, its more
favourable pharmacokinetic properties, its availability in either
parenteral or enteral formulation, and its safer toxicity and drug
interaction profile.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Our results demonstrate that antifungal prophylaxis, particularly
with fluconazole, is eDective in preventing invasive fungal
infections and total mortality in non-neutropenic critically ill
patients, although the optimal dose and duration of prophylaxis
remain uncertain. Antifungal prophylaxis with fluconazole should
therefore be considered for patients at increased risk of invasive
fungal infections.
Implications for research
The prospective identification of patients at increased risk, who
may most benefit from antifungal prophylaxis, from amongst
the general population of critically ill patients requires further
research. Although many risk factors for fungal infections have
been defined, these require integration into risk predictive
algorithms (Ostrosky 2003; Paphitou 2005). The cost-eDectiveness
of antifungal prophylaxis strategies also has not been defined
- awaiting, in part, a clearer understanding of the attributable
clinical and economic consequences of invasive fungal infections in
critically ill patients.
The selection or generation of resistance to antifungal agents
among fungal pathogens remains a major potential concern
and further study quantifying such potential ecological eDects is
required before the widespread adoption of antifungal prophylaxis
can be recommended.
The significant eDect of antifungal prophylaxis with fluconazole
and ketoconazole on total mortality demonstrated in this study
is promising and potentially clinically important; this requires
confirmation in appropriately powered trials.
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Methods Random sequence generation: Yes (block) 
Allocation concealment: Unclear 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: No 
Number excluded /number randomized: 6/125 (5%)
Participants Inclusion: trauma or surgical patients, expected length of stay >48 hours, >1 risk factor (e.g. central ve-
nous line, total parenteral nutrition, mechanical ventilation, antibiotics etc) 
Number randomised: 125 
Percentage post-surgical: >30%Candida at baseline: 24% 
Percentage colonized with Candida at baseline: 24%
Interventions 1. Fluconazole 800 mg/day intravenously (IV) initially then 400 mg/day IV or orally 
2. Placebo
Intervention duration: until ICU discharge (maximum 6 weeks)
Outcomes Mortality 
Proven IFI 
Suspected IFI 
Proven IFI with azole-resistant species 
Superficial FI 
Fungal colonization 
Fungal colonization with azole-resistant species 
Adverse events
Follow-up duration: until hospital discharge
Notes Country: USA 
Setting: single hospital, adult ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Ables 2000 
 
 
Methods Random sequence generation: Yes (computer) 
Allocation concealment: Yes (central allocation) 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Yes 
Intention-to-treat analysis: Yes 
Number excluded /number randomized: 0/234 (0%)
Participants Inclusion: acute lung injury 
Number randomized: 234 
Percentage post-surgical: not stated 
Percentage colonized with Candida at baseline: not stated
Interventions 1. Ketoconazole 400 mg/day orally 
2. Placebo
Intervention duration: until 48 hours post-extubation
ARDS Network 2000 
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Outcomes Mortality 
Adverse events
Follow-up duration: not stated
Notes Country: USA 
Setting: 24 hospitals, adult ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Low risk A - Adequate
ARDS Network 2000  (Continued)
 
 
Methods Random sequence generation: Yes (block) 
Allocation concealment: Yes (pharmacy allocation) 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Yes 
Intention-to-treat analysis: No 
Number excluded /number randomized: 6/49 (12%)
Participants Inclusion: recent abdominal surgery, recurrent gastrointestinal tract perforation, or anastomotic leak-
age 
Number randomized: 49 
Percentage post-surgical: 100% 
Percentage colonized with Candida at baseline: 40%
Interventions 1. Fluconazole 400 mg/day IV 
2. Placebo
Intervention duration: until "complete resolution of intra-abdominal disease" (median 15-17 days)
Outcomes Mortality 
Proven IFI 
Proven IFI with azole-resistant species. 
Fungal colonization 
Fungal colonization with azole-resistant species 
Adverse events
Follow-up duration: until one week post-prophylaxis
Notes Country: Switzerland 
Setting: two hospitals, adult surgical/medical ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Eggimann 1999 
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Methods Random sequence generation: Unclear 
Allocation concealment: Yes ("blinded list") 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: Unclear 
Number excluded /number randomized: 16/220 (7%)
Participants Inclusion: mechaniscal ventilation >48 hours and expected further 72 hours 
Number randomized: 220 
Percentage post-surgical: 60% 
Percentage colonized with Candida at baseline: 48%
Interventions 1. Fluconazole 100 mg/day IV 
2. Placebo
Intervention duration: until withdrawal from mechanical ventilation
Outcomes Mortality 
Proven IFI 
Suspected IFI 
Proven IFI with azole-resistant species 
Superficial FI 
Fungal colonization 
Fungal colonization with azole-resistant species 
Adverse events
Follow-up duration: at least 30 days
Notes Country: Switzerland 
Setting: single hospital, adult surgical/medical ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Garbino 2002 
 
 
Methods Random sequence generation: Unclear 
Allocation concealment: Unclear 
Blinding (subjects/investigators): Unclear 
Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: Yes 
Number excluded /number randomized: 0/70 (0%)
Participants Inclusion: severe pancreatitis with at least one of "elderly", organ dysfunction, total parenteral nutri-
tion, corticosteroids, gastrointestinal fistula, broad-spectrum antibiotics) 
Number randomized: 70 
Percentage post-surgical: not stated 
Percentage colonized with Candida at baseline: not stated
Interventions 1. Fluconazole 100 mg/day IV 
2. "Garlicin" 120 mg/day IV 
3. Control (neither fluconazole or "garlicin")
He 2003 
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Intervention duration: "until relief of predisposing condition"
Outcomes Proven IFI
Follow-up duration: not stated
Notes Country: China 
Setting: ?single hospital, ?ward and/or ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
He 2003  (Continued)
 
 
Methods Random sequence generation: Uclear 
Allocation concealment: Yes (pharmacy allocation) 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: Yes 
Number excluded /number randomized: 0/71 (0%)
Participants Inclusion: septic shock from gastrointestinal tract perforation or nosocomial pneumonia 
Number randomized: 71 
Percentage post-surgical: 65% 
Percentage colonized with Candida at baseline: 6%
Interventions 1. Fluconazole 200 mg/day IV 
2. Placebo
Intervention duration: for duration of septic shock
Outcomes Mortality 
Proven IFI 
Proven IFI with azole-resistant species 
Fungal colonization
Follow-up duration: 30 days
Notes Country: Saudi Arabia 
Setting: single hospital, adult surgical/medical ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Jacobs 2003 
 
 
Methods Random sequence generation: Unclear 
Allocation concealment: Unclear (envelopes ?sealed) 
Blinding (subjects/investigators): Unclear 
Parizkova 2000 
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Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: Yes 
Number excluded /number randomized: 0/38 (0%)
Participants Inclusion: admitted to ICU <5 days, receipt of antibiotics >24 hours, mechaniscal ventilation >48 hours 
Number randomized: 38 
Percentage post-surgical: >37% 
Percentage colonized with Candida at baseline: not stated
Interventions 1. Fluconazole 100 mg/day IV 
2. Control (no fluconazole)
Intervention duration: for duration of ICU admission
Outcomes Mortality 
Proven IFI 
Proven IFI with azole-resistant species 
Fungal colonization 
Fungal colonization with azole-resistant species
Follow-up duration: not stated
Notes Country: Czech Republic 
Setting: single hospital, adult ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Parizkova 2000  (Continued)
 
 
Methods Random sequence generation: Yes (block) 
Allocation concealment: Yes (pharmacy allocation) 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Yes 
Intention-to-treat analysis: Yes 
Number excluded /number randomized: 0/260 (0%)
Participants Inclusion: expected length of ICU stay >3 days 
Number randomized: 260 
Percentage post-surgical: 91% 
Percentage colonized with Candida at baseline: 75%
Interventions 1. Fluconazole 800 mg orally then 400 mg/day orally 
2.Placebo
Intervention duration: until ICU discharge (mean 5 days)
Outcomes Mortality 
Proven IFI 
Suspected IFI 
Proven IFI with azole-resistant species 
Superficial FI
Follow-up duration: until 3 days post-ICU discharge
Pelz 2001 
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Notes Country: USA 
Setting: single hospital, adult surgical ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Pelz 2001  (Continued)
 
 
Methods Random sequence generation: Yes (computer) 
Allocation concealment: Yes (computer allocation) 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: Yes 
Number excluded /number randomized: 8/117 (7%)
Participants Inclusion: gastrointestinal perforation 
Number randomized: 117 
Percentage post-surgical: 100% 
Percentage colonized with Candida at baseline: not stated
Interventions 1. Fluconazole 400 mg IV single dose 
2. Placebo
Intervention duration: single dose
Outcomes Mortality 
Proven IFI 
Suspected IFI
Follow-up duration: not stated
Notes Country: Norway 
Setting: 13 hospitals, adult surgical patients
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Sandven 2002 
 
 
Methods Random sequence generation: Unclear 
Allocation concealment: Yes (sealed envelopes) 
Blinding (subjects/investigators): No 
Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: No 
Number excluded /number randomized: 0/292 (0%)
Participants Inclusion: expected length of stay >48 hours 
Number randomized: 292 
Savino 1994 
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Percentage post-surgical: 79% 
Percentage colonized with Candida at baseline: not stated
Interventions 1. Ketoconazole 200 mg/day orally 
2. Clotrimazole 30 mg/day orally 
3. Nystatin 8 million units/day orally 
4. Control (no antifungal)
Intervention duration: until ICU discharge (mean 8-16 days)
Outcomes Mortality 
Proven IFI 
Fungal colonization
Follow-up duration: not stated
Notes Country: USA 
Setting: single hospital, adult surgical ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Savino 1994  (Continued)
 
 
Methods Random sequence generation: Unclear 
Allocation concealment: Unclear 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: No 
Number excluded /number randomized: 17/74 (23%)
Participants Inclusion: >2 risk factors, no fungal colonization 
Number randomized: 74 
Percentage post-surgical: 97% 
Percentage colonized with Candida at baseline: 20%
Interventions 1. Ketoconazole 200 mg/day orally 
2. Placebo
Intervention duration: until ICU discharge (maximum 21 days)
Outcomes Mortality 
Proven IFI 
Proven IFI with azole-resistant species 
Fungal colonization 
Fungal colonization with azole-resistant species
Follow-up duration: not stated
Notes Country: USA 
Setting: single hospital, adult surgical ICU
Risk of bias
Slotman 1987 
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Bias Authors' judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Slotman 1987  (Continued)
 
 
Methods Random sequence generation: Unclear 
Allocation concealment: Unclear 
Blinding (subjects/investigators): Yes 
Blinding (outcome assessors): Unclear 
Intention-to-treat analysis: Yes 
Number excluded /number randomized: 0/56 (0%)
Participants Inclusion: sepsis 
Number randomized: 56 
Percentage post-surgical: ?100% 
Percentage colonized with Candida at baseline: not stated
Interventions 1. Ketoconazole 400 mg/day orally 
2. Placebo
Intervention duration: until ICU discharge (maximum 21 days)
Outcomes Mortality 
Fungal colonization 
Adverse events
Follow-up duration: not stated
Notes Country: USA 
Setting: single hospital, adult surgical ICU
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Yu 1993 
FI = fungal infections
IFI = invasive fungal infections
IV = intraveneous
ICU = intensive care unit
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Allen 2000 Intervention (glutamine-containing total parenteral nutrition fluid) not relevant
Bellman 1995 Commentary
DeVries 1998 Review
Earl-Salotti 1995 Review
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Study Reason for exclusion
Evans 1975 Not randomized
Frazee 1995 Review
Kicklighter 2001 Participants not relevant (neonates)
Moral 1994 Not randomized
Ohnmacht 2001 Participants not relevant (patients receiving interleukin-2)
Rosemurgy 1995 Outcomes not relevant
Schilling 2001 Not randomized
Van Saene 2002 Review
Vandewoude 1997 Not randomized
Wainer 1992 Participants not relevant (neonates)
Weydert 1971 Intervention not relevant (selective decontamination of the digestive tract)
Yahwak 2002 Review
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Systemic antifungal versus placebo/no antifungal/nonabsorbable antifungal
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mortality 11 1500 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.59, 0.97]
1.1 Fluconazole 7 849 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.07]
1.2 Ketoconazole 4 651 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.42, 1.12]
2 Proven invasive fungal infection 10 1260 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.31, 0.68]
2.1 Fluconazole 8 897 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.32, 0.71]
2.2 Ketoconazole 2 363 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.07, 1.31]
3 Proven invasive fungal infection
(azole-resistant Candida species)
7 805 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.22, 1.72]
3.1 Fluconazole 6 734 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.22, 1.96]
3.2 Ketoconazole 1 71 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.14]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 Proven invasive fungal infection
(moulds)
7 805 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Fluconazole 6 734 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Ketoconazole 1 71 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Suspected invasive fungal infection 4 696 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.25, 5.13]
5.1 Fluconazole 4 696 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.25, 5.13]
5.2 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Proven or suspected invasive fungal
infection
4 696 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.40, 1.02]
6.1 Fluconazole 4 696 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.40, 1.02]
6.2 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Superficial fungal infection 3 587 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.27, 1.29]
7.1 Fluconazole 3 587 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.27, 1.29]
7.2 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Fungal colonization 8 792 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.50, 0.73]
8.1 Fluconazole 5 375 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.42, 0.74]
8.2 Ketoconazole 3 417 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.47, 0.94]
9 Fungal colonization (azole-resistant
Candida species)
5 309 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.44, 2.95]
9.1 Fluconazole 4 252 Risk Ratio (M-H, Random, 95% CI) 1.74 [0.64, 4.71]
9.2 Ketoconazole 1 57 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.02, 1.44]
10 Adverse effects requiring cessation 5 655 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.37, 1.94]
10.1 Fluconazole 3 367 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.22, 2.57]
10.2 Ketoconazole 2 288 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.20, 7.59]
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Analysis 1.1.   Comparison 1 Systemic antifungal versus placebo/
no antifungal/nonabsorbable antifungal, Outcome 1 Mortality.
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Fluconazole  
Ables 2000 12/60 12/60 8.69% 1[0.49,2.05]
Eggimann 1999 7/23 10/20 7.99% 0.61[0.29,1.3]
Garbino 2002 41/105 43/103 20.26% 0.94[0.67,1.3]
Jacobs 2003 7/32 21/39 8.68% 0.41[0.2,0.83]
Parizkova 2000 4/18 0/20 0.74% 9.95[0.57,172.84]
Pelz 2001 14/130 16/130 9.45% 0.88[0.45,1.72]
Sandven 2002 4/53 8/56 4.11% 0.53[0.17,1.65]
Subtotal (95% CI) 421 428 59.93% 0.77[0.56,1.07]
Total events: 89 (Antifungal), 110 (Control)  
Heterogeneity: Tau2=0.06; Chi2=8.73, df=6(P=0.19); I2=31.31%  
Test for overall effect: Z=1.54(P=0.12)  
   
1.1.2 Ketoconazole  
ARDS Network 2000 41/117 40/117 19.31% 1.02[0.72,1.46]
Savino 1994 4/65 37/227 5.19% 0.38[0.14,1.02]
Slotman 1987 11/35 15/36 10.53% 0.75[0.4,1.41]
Yu 1993 4/26 11/28 5.04% 0.39[0.14,1.08]
Subtotal (95% CI) 243 408 40.07% 0.68[0.42,1.12]
Total events: 60 (Antifungal), 103 (Control)  
Heterogeneity: Tau2=0.13; Chi2=6.28, df=3(P=0.1); I2=52.26%  
Test for overall effect: Z=1.51(P=0.13)  
   
Total (95% CI) 664 836 100% 0.76[0.59,0.97]
Total events: 149 (Antifungal), 213 (Control)  
Heterogeneity: Tau2=0.05; Chi2=14.81, df=10(P=0.14); I2=32.48%  
Test for overall effect: Z=2.18(P=0.03)  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.2.   Comparison 1 Systemic antifungal versus placebo/no antifungal/
nonabsorbable antifungal, Outcome 2 Proven invasive fungal infection.
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Fluconazole  
Ables 2000 8/61 12/60 21.9% 0.66[0.29,1.49]
Eggimann 1999 4/25 9/22 13.93% 0.39[0.14,1.09]
Garbino 2002 5/104 11/102 14.14% 0.45[0.16,1.24]
He 2003 2/22 7/23 6.93% 0.3[0.07,1.28]
Jacobs 2003 0/32 1/39 1.47% 0.4[0.02,9.59]
Parizkova 2000 0/18 0/20   Not estimable
Pelz 2001 7/130 16/130 20.21% 0.44[0.19,1.03]
Sandven 2002 5/53 10/56 14.58% 0.53[0.19,1.44]
Subtotal (95% CI) 445 452 93.17% 0.47[0.32,0.71]
Total events: 31 (Antifungal), 66 (Control)  
Heterogeneity: Tau2=0; Chi2=1.22, df=6(P=0.98); I2=0%  
Favours antifungal 100.1 50.2 20.5 1 Favours control
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Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=3.67(P=0)  
   
1.2.2 Ketoconazole  
Savino 1994 1/65 8/227 3.47% 0.44[0.06,3.43]
Slotman 1987 1/35 5/36 3.36% 0.21[0.03,1.67]
Subtotal (95% CI) 100 263 6.83% 0.3[0.07,1.31]
Total events: 2 (Antifungal), 13 (Control)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=1.6(P=0.11)  
   
Total (95% CI) 545 715 100% 0.46[0.31,0.68]
Total events: 33 (Antifungal), 79 (Control)  
Heterogeneity: Tau2=0; Chi2=1.82, df=8(P=0.99); I2=0%  
Test for overall effect: Z=3.96(P<0.0001)  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Systemic antifungal versus placebo/no antifungal/nonabsorbable
antifungal, Outcome 3 Proven invasive fungal infection (azole-resistant Candida species).
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Fluconazole  
Ables 2000 0/60 2/58 11.61% 0.19[0.01,3.94]
Eggimann 1999 1/23 1/20 14.42% 0.87[0.06,13.02]
Garbino 2002 1/103 0/101 10.38% 2.94[0.12,71.39]
Jacobs 2003 0/32 0/39   Not estimable
Parizkova 2000 0/18 0/20   Not estimable
Pelz 2001 3/130 5/130 53.06% 0.6[0.15,2.46]
Subtotal (95% CI) 366 368 89.48% 0.66[0.22,1.96]
Total events: 5 (Antifungal), 8 (Control)  
Heterogeneity: Tau2=0; Chi2=1.54, df=3(P=0.67); I2=0%  
Test for overall effect: Z=0.75(P=0.46)  
   
1.3.2 Ketoconazole  
Slotman 1987 0/35 1/36 10.52% 0.34[0.01,8.14]
Subtotal (95% CI) 35 36 10.52% 0.34[0.01,8.14]
Total events: 0 (Antifungal), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
Total (95% CI) 401 404 100% 0.62[0.22,1.72]
Total events: 5 (Antifungal), 9 (Control)  
Heterogeneity: Tau2=0; Chi2=1.69, df=4(P=0.79); I2=0%  
Test for overall effect: Z=0.92(P=0.36)  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
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Analysis 1.4.   Comparison 1 Systemic antifungal versus placebo/no antifungal/
nonabsorbable antifungal, Outcome 4 Proven invasive fungal infection (moulds).
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 Fluconazole  
Ables 2000 0/60 0/58   Not estimable
Eggimann 1999 0/23 0/20   Not estimable
Garbino 2002 0/103 0/101   Not estimable
Jacobs 2003 0/32 0/39   Not estimable
Parizkova 2000 0/18 0/20   Not estimable
Pelz 2001 0/130 0/130   Not estimable
Subtotal (95% CI) 366 368 Not estimable
Total events: 0 (Antifungal), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.4.2 Ketoconazole  
Slotman 1987 0/35 0/36   Not estimable
Subtotal (95% CI) 35 36 Not estimable
Total events: 0 (Antifungal), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 401 404 Not estimable
Total events: 0 (Antifungal), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.5.   Comparison 1 Systemic antifungal versus placebo/no antifungal/
nonabsorbable antifungal, Outcome 5 Suspected invasive fungal infection.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 Fluconazole  
Ables 2000 5/61 1/60 23.86% 4.92[0.59,40.86]
Garbino 2002 1/104 3/102 22.52% 0.33[0.03,3.09]
Pelz 2001 2/130 6/130 30.2% 0.33[0.07,1.62]
Sandven 2002 4/53 1/56 23.42% 4.23[0.49,36.61]
Subtotal (95% CI) 348 348 100% 1.14[0.25,5.13]
Total events: 12 (Treatment), 11 (Control)  
Heterogeneity: Tau2=1.29; Chi2=6.72, df=3(P=0.08); I2=55.37%  
Test for overall effect: Z=0.18(P=0.86)  
   
1.5.2 Ketoconazole  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Treatment), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 348 348 100% 1.14[0.25,5.13]
Total events: 12 (Treatment), 11 (Control)  
Heterogeneity: Tau2=1.29; Chi2=6.72, df=3(P=0.08); I2=55.37%  
Test for overall effect: Z=0.18(P=0.86)  
Test for subgroup differences: Not applicable  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.6.   Comparison 1 Systemic antifungal versus placebo/no antifungal/
nonabsorbable antifungal, Outcome 6 Proven or suspected invasive fungal infection.
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 Fluconazole  
Ables 2000 13/61 13/60 29.62% 0.98[0.5,1.94]
Garbino 2002 6/104 14/102 19.59% 0.42[0.17,1.05]
Pelz 2001 9/130 22/130 26.76% 0.41[0.2,0.85]
Sandven 2002 9/53 11/56 24.03% 0.86[0.39,1.92]
Subtotal (95% CI) 348 348 100% 0.64[0.4,1.02]
Total events: 37 (Antifungal), 60 (Control)  
Heterogeneity: Tau2=0.07; Chi2=4.35, df=3(P=0.23); I2=31.07%  
Test for overall effect: Z=1.89(P=0.06)  
   
1.6.2 Ketoconazole  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 348 348 100% 0.64[0.4,1.02]
Total events: 37 (Antifungal), 60 (Control)  
Heterogeneity: Tau2=0.07; Chi2=4.35, df=3(P=0.23); I2=31.07%  
Test for overall effect: Z=1.89(P=0.06)  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.7.   Comparison 1 Systemic antifungal versus placebo/no
antifungal/nonabsorbable antifungal, Outcome 7 Superficial fungal infection.
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.7.1 Fluconazole  
Ables 2000 4/61 7/60 43.51% 0.56[0.17,1.82]
Garbino 2002 2/104 6/102 24.19% 0.33[0.07,1.58]
Pelz 2001 4/130 4/130 32.3% 1[0.26,3.91]
Subtotal (95% CI) 295 292 100% 0.59[0.27,1.29]
Total events: 10 (Antifungal), 17 (Control)  
Heterogeneity: Tau2=0; Chi2=1.12, df=2(P=0.57); I2=0%  
Favours antifungal 100.1 50.2 20.5 1 Favours control
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
30
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.32(P=0.19)  
   
1.7.2 Ketoconazole  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 295 292 100% 0.59[0.27,1.29]
Total events: 10 (Antifungal), 17 (Control)  
Heterogeneity: Tau2=0; Chi2=1.12, df=2(P=0.57); I2=0%  
Test for overall effect: Z=1.32(P=0.19)  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.8.   Comparison 1 Systemic antifungal versus placebo/no
antifungal/nonabsorbable antifungal, Outcome 8 Fungal colonization.
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.8.1 Fluconazole  
Ables 2000 14/60 32/57 14.43% 0.42[0.25,0.69]
Eggimann 1999 7/23 14/20 8.18% 0.43[0.22,0.86]
Garbino 2002 29/55 40/51 45.53% 0.67[0.5,0.9]
Jacobs 2003 2/32 4/39 1.43% 0.61[0.12,3.12]
Parizkova 2000 18/18 20/20   Not estimable
Subtotal (95% CI) 188 187 69.56% 0.55[0.42,0.74]
Total events: 70 (Antifungal), 110 (Control)  
Heterogeneity: Tau2=0.02; Chi2=3.61, df=3(P=0.31); I2=16.86%  
Test for overall effect: Z=4.02(P<0.0001)  
   
1.8.2 Ketoconazole  
Savino 1994 9/65 50/227 8.87% 0.63[0.33,1.21]
Slotman 1987 16/35 23/36 19.9% 0.72[0.46,1.11]
Yu 1993 2/26 6/28 1.67% 0.36[0.08,1.62]
Subtotal (95% CI) 126 291 30.44% 0.66[0.47,0.94]
Total events: 27 (Antifungal), 79 (Control)  
Heterogeneity: Tau2=0; Chi2=0.83, df=2(P=0.66); I2=0%  
Test for overall effect: Z=2.28(P=0.02)  
   
Total (95% CI) 314 478 100% 0.6[0.5,0.73]
Total events: 97 (Antifungal), 189 (Control)  
Heterogeneity: Tau2=0; Chi2=4.73, df=6(P=0.58); I2=0%  
Test for overall effect: Z=5.11(P<0.0001)  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
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Analysis 1.9.   Comparison 1 Systemic antifungal versus placebo/no antifungal/
nonabsorbable antifungal, Outcome 9 Fungal colonization (azole-resistant Candida species).
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.9.1 Fluconazole  
Ables 2000 2/60 2/57 21.51% 0.95[0.14,6.52]
Eggimann 1999 2/23 1/20 15.39% 1.74[0.17,17.78]
Garbino 2002 3/24 2/30 26.47% 1.88[0.34,10.33]
Parizkova 2000 3/18 1/20 17.39% 3.33[0.38,29.25]
Subtotal (95% CI) 125 127 80.76% 1.74[0.64,4.71]
Total events: 10 (Antifungal), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=0.73, df=3(P=0.87); I2=0%  
Test for overall effect: Z=1.09(P=0.28)  
   
1.9.2 Ketoconazole  
Slotman 1987 1/27 6/30 19.24% 0.19[0.02,1.44]
Subtotal (95% CI) 27 30 19.24% 0.19[0.02,1.44]
Total events: 1 (Antifungal), 6 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
   
Total (95% CI) 152 157 100% 1.13[0.44,2.95]
Total events: 11 (Antifungal), 12 (Control)  
Heterogeneity: Tau2=0.14; Chi2=4.54, df=4(P=0.34); I2=11.82%  
Test for overall effect: Z=0.26(P=0.8)  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.10.   Comparison 1 Systemic antifungal versus placebo/no antifungal/
nonabsorbable antifungal, Outcome 10 Adverse e?ects requiring cessation.
Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.10.1 Fluconazole  
Ables 2000 0/61 2/59 7.28% 0.19[0.01,3.95]
Eggimann 1999 0/23 0/20   Not estimable
Garbino 2002 4/103 4/101 32.6% 0.98[0.25,3.81]
Subtotal (95% CI) 187 180 39.88% 0.75[0.22,2.57]
Total events: 4 (Antifungal), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=0.95, df=1(P=0.33); I2=0%  
Test for overall effect: Z=0.46(P=0.64)  
   
1.10.2 Ketoconazole  
ARDS Network 2000 4/117 1/117 13.65% 4[0.45,35.25]
Yu 1993 4/26 7/28 46.47% 0.62[0.2,1.86]
Subtotal (95% CI) 143 145 60.12% 1.24[0.2,7.59]
Total events: 8 (Antifungal), 8 (Control)  
Heterogeneity: Tau2=1.05; Chi2=2.35, df=1(P=0.13); I2=57.44%  
Test for overall effect: Z=0.23(P=0.82)  
   
Total (95% CI) 330 325 100% 0.85[0.37,1.94]
Favours antifungal 100.1 50.2 20.5 1 Favours control
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Study or subgroup Antifungal Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 12 (Antifungal), 14 (Control)  
Heterogeneity: Tau2=0.06; Chi2=3.25, df=3(P=0.35); I2=7.81%  
Test for overall effect: Z=0.39(P=0.7)  
Test for subgroup differences: Not applicable  
Favours antifungal 100.1 50.2 20.5 1 Favours control
 
 
A D D I T I O N A L   T A B L E S
 
Trial Proven IFI Suspected IFI Superficial FI
Ables 2000 "Documented candidiasis": positive culture from respiratory, mu-
cosal, or peritoneal specimens
Compatible clinical illness
(including SIRS) but no evi-
dence of bacterial or other
cause
Fungal UTI,
thrush, skin
lesions
Eggimann
1999
Clinical plus positive culture/histology of sterile site specimen or
abdominal drain effluent
NA NA
Garbino
2002
Clinical plus positive culture of sterile site specimen or BAL
(>10,000 cfu/mL) with radiological infiltrates
Commencement of systemic
antifungal therapy with clini-
cal but no microbiological ev-
idence of IFI
Fungal super-
ficial wound,
UTI, or muco-
cutaneous in-
fection
He 2003 Clinical plus positive culture from sterile site specimen or bile,
sputum, pus, throat, urine, or stool
NA NA
Jacobs 2003 Positive culture/histology of sterile site specimen NA Culture of mu-
cosal surface
specimens
Parizkova
2000
Clinical plus positive culture/histology of sterile site specimen NA Clinical plus
culture of su-
perficial site
specimens
Pelz 2001 Clinical plus positive culture/histology of sterile site specimen, in-
tradermal catheter tip (>15 cfu), or deep surgical site specimen (on
debridement)
Commencement of anti-
fungal therapy with clinical
evidence of IFI and fungal
colonisation
Fungal UTI
Sandven
2002
Clinical plus positive culture of blood, intrabdominal drain fluid,
or other (unspecified) sites
Commencement of systemic
antifungal therapy with clini-
cal but no microbiological ev-
idence of IFI
NA
Savino 1994 Positive culture of sterile site specimen or > 2 other (unspecified)
sites
NA NA
Slotman
1987
Positive culture of sterile site or invasive burn wound NA NA
Table 1.   Definitions of fungal infections used in included studies 
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Weidemann
2000
NA NA NA
Yu 1993 NA NA NA
Table 1.   Definitions of fungal infections used in included studies  (Continued)
 
 
Variable Category No. studies RR (95%CI) IFI
SUBGROUP ANALYSES:      
Definition of invasive fungal infection conforms
to that used in this review
Yes 5 0.41 (0.24 to 0.69)
  No 4 0.53 (0.30 to 0.93)
Fluconazole dose >/=400 mg/day 4 0.50 (0.30 to 0.80)
  <400 mg/day 3 0.39 (0.17 to 0.88)
Post-surgical patients (%) >/=75% 5 0.43 (0.26 to 0.71)
  <75% 3 0.56 (0.03 to 1.04)
SENSITIVITY ANALYSES:      
Analysis model Random effects   0.46 (0.31 to 0.68)
  Fixed effects   0.45 (0.31 to 0.66)
Randomized sequence generation Adequate 4 0.50 (0.32 to 0.80)
  Uncertain 5 0.37 (0.18 to 0.75)
Allocation concealment Adequate 6 0.45 (0.28 to 0.71)
  Uncertain 3 0.49 (0.25 to 0.97)
Blinding of outcome assessors Yes 2 0.42 (0.22 to 0.81)
  No 7 0.48 (0.30 to 0.78)
Intention-to-treat analysis Yes 4 0.44 (0.24 to 0.78)
  No 5 0.48 (0.29 to 0.80)
Table 2.   Subgroup and sensitivity analyses 
 
 
Estimat-
ed risk
Examples Incid. w/
o prophy-
lax
Incid. w/
prophy-
lax
No.
avoided
NNT
(95%CI)
Table 3.   Applicability of meta-analysis results 
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Low (1%) Absence of risk factors (based on Rex 2001) 1 0.47 0.53 188
(147-345)
Average
(2%)
Unselected ICU population (based on Rex 2001) 2 0.94 1.06 94
(74-172)
High
(11%)
One of new onset haemodialysis, diabetes, total parenteral nutri-
tion prior to ICU entry, or broad-spectrum antibiotics (based on
Paphitou 2005)
11 5.2 5.8 17 (13-31)
High
(17%)
One of new onset haemodialysis, diabetes, or total parenteral
nutrition prior to ICU entry (based on Paphitou 2005)
17 8.0 9.0 11 (9-20)
Highest
(20%)
One of new onset haemodialysis, diabetes, or total parenter-
al nutrition prior to ICU entry AND broad-spectrum antibiotics
(based on Paphitou 2005)
20 9.4 10.6 9 (7-17)
Table 3.   Applicability of meta-analysis results  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Search strategies for electronic databases
 
Database Search strategy
Cochrane Central Register of
Controlled Trials
#1 MeSH descriptor Antifungal Agents explode all trees in MeSH products 
#2 antifungal in All Fields, from 1800 to 2004 in all products 
#3 fluconazole in All Fields, from 1800 to 2004 in all products 
#4 itraconazole in All Fields, from 1800 to 2004 in all products 
#5 ketoconazole in All Fields in all products 
#6 voriconazole in All Fields in all products 
#7 amphotericin in All Fields in all products 
#8 ambisome in All Fields in all products 
#9 amphotec in All Fields in all products 
#10 amphocil in All Fields in all products 
#11 abelcet in All Fields in all products 
#12 caspofungin in All Fields in all products 
#13 flucytosine in All Fields in all products 
#14 miconazole in All Fields in all products 
#15 econazole in All Fields in all products 
#16 clotrimazole in All Fields in all products 
#17 nystatin in All Fields in all products 
#18 MeSH descriptor Mycoses explode all trees in MeSH products 
#19 fung* in All Fields in all products 
#20 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR
#15 OR #16 OR #17 OR #18 OR #19) 
#21 MeSH descriptor Critical Care explode all trees in MeSH products 
#22 intensive in All Fields in all products 
#23 critic* in All Fields in all products 
#24 surg* in All Fields in all products 
#25 (#21 OR #22 OR #23 OR #24) 
#26 (#20 AND #25)
MEDLINE (OVID) 1 exp antifungal agents/ 
2 exp mycoses/ 
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3 fung$.tw. 
4 fluconazole.tw. 
5 diflucan.tw. 
6 itraconazole.tw. 
7 sporanox.tw. 
8 ketoconazole.tw. 
9 nizoral.tw. 
10 voriconazole.tw. 
11 amphotericin.tw. 
12 ambisome.tw. 
13 amphotec.tw. 
14 abelcet.tw. 
15 flucytosine.tw. 
16 nystatin.tw. 
17 miconazole.tw. 
18 (echinocandin$ or caspofungin).tw. 
19 (select$ adj5 decontam$).tw. 
20 or/1-19 
21 exp Intensive Care Units/ 
22 intensive care.tw. 
23 critical$.tw. 
24 surg$.tw. 
25 or/21-24 
26 20 and 25 
27 randomized controlled trial.pt. 
28 controlled clinical trial.pt. 
29 randomized controlled trials/ 
30 Random allocation/ 
31 Double-blind method/ 
32 Single-blind method/ 
33 exp Evaluation studies/ 
34 exp clinical-trials/ 
35 clinical trial.pt. 
36 (clin$ adj5 trial$).tw. 
37 ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw. 
38 exp Placebos/ 
39 placebo$.tw. 
40 random$.tw. 
41 exp Research design/ 
42 or/27-41 
43 26 and 42
EMBASE (OVID) 1 exp antifungal agent/ 
2 fluconazole.tw. 
3 diflucan.tw. 
4 itraconazole.tw. 
5 sporanox.tw. 
6 ketoconazole.tw. 
7 nizoral.tw. 
8 voriconazole.tw. 
9 vfend.tw. 
10 amphotericin.tw. 
11 ambisome.tw. 
12 amphotec.tw. 
13 amphocil.tw. 
14 abelcet.tw. 
15 fungizone.tw. 
16 flucytosine.tw. 
17 nystatin.tw. 
18 miconazole.tw. 
19 echinocandin$.tw. 
  (Continued)
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20 caspofungin.tw. 
21 (select$ adj decontam$).tw. 
22 exp mycosis/ 
23 fung$.tw. 
24 or/1-23 
25 exp intensive care unit/ 
26 intensive.tw. 
27 critic$.tw. 
28 surg$.tw. 
29 or/25-28 
30 24 and 29 
31 exp controlled study/ or controlled study.ti,ab,hw,tn,mf. 
32 exp statistical analysis/ or clinical study.ti,ab,hw,tn,mf. 
33 exp major clinical study/ or major clinical study.ti,ab,hw,tn,mf. 
34 exp randomized controlled trial/ or randomised controlled study.ti,ab,hw,tn,mf. 
35 exp randomized controlled trial/ or randomized controlled study.ti,ab,hw,tn,mf. 
36 random$.ti,ab,hw,tn,mf. 
37 exp double blind procedure/ or double blind procedure.ti,ab,hw,tn,mf. 
38 exp single blind procedure/ or single blind procedure.ti,ab,hw,tn,mf. 
39 exp multicenter study/ or multicenter study.ti,ab,hw,tn,mf. 
40 exp placebo/ or placebo.ti,ab,hw,tn,mf. 
41 or/31-40 
42 (human not animal).sh,de,hw. 
43 41 and 42 
44 30 and 43
  (Continued)
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Medical Subject Headings (MeSH)
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